Chikungunya Vaccine Candidate: Valneva completes recruitment for Phase 3 trial

Vaccine company, Valneva, announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV). The primary endpoint of the [...]

The post Chikungunya Vaccine Candidate: Valneva completes recruitment for Phase 3 trial appeared first on Outbreak News Today.